Treatment
Tocilizumab clinical trials
We’re tracking 54 recruiting studies that include Tocilizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06654154Recruiting
Vitamin B12 as a marker for disease activity in tocilizumab patients
This study looks at whether vitamin B12 levels in the blood can help tell if your disease is active or if you have an infection while being treated with tocilizumab. The goal is to find a simple way to monitor your condition without extra invasive tests.
Clermont-FerrandAges 18 years+ - NCT06927375RecruitingPhase 4
Combination drug therapy for thyroid eye disease
This study tests a combination of two drugs, tocilizumab and flupentixol-melitracen, in people with active, moderate-to-severe thyroid-associated eye disease (TED). It aims to see if this combination can reduce eye bulging, double vision, and anxiety symptoms.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Atlanta, GeorgiaAges 50 years+ - NCT06430736RecruitingPhase 2
Tocilizumab before or during CAR-T therapy
This study tests whether giving tocilizumab (a drug that calms inflammation) before CAR-T cell therapy helps prevent side effects. It compares using it ahead of time versus only when needed. You may be eligible if you are scheduled for CAR-T therapy for lymphoma, leukemia, or myeloma.
Bern, Canton of BernAges 18 years+ - NCT06033196RecruitingPhase 2
Tocilizumab after lung transplant
This study tests whether the drug tocilizumab can help prevent your body from rejecting a new lung after transplant. It might help improve the success of your transplant by reducing immune system activity.
Phoenix, ArizonaAges 12–75 - NCT04300686RecruitingPhase 4
Pilot study for severe Takayasu artery inflammation
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
Shanghai, Shanghai MunicipalityAges 14–100 - NCT07801638Recruiting
Anticoagulation plus tocilizumab for cerebral venous thrombosis
This trial tests a combination of blood thinners (anticoagulation) and a drug called tocilizumab, which targets inflammation, to treat acute cerebral venous thrombosis (a blood clot in a vein in the brain). It aims to see if this combined treatment improves recovery and reduces complications compared to blood thinners alone.
Beijing, Beijing MunicipalityAges 18–80 - NCT05845723RecruitingPhase 2
Study drugs for blood-vessel Behçet’s to reduce inflammation
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
Beijing, Beijing MunicipalityAges 18–65 - NCT07609940RecruitingPhase 4
Linvoseltamab plus tocilizumab for heavily treated multiple myeloma
This trial tests a combination of two drugs (linvoseltamab and tocilizumab) for adults with multiple myeloma that has stopped responding to standard treatments. Tocilizumab is added to help reduce serious side effects from the main drug.
Los Angeles, CaliforniaAges 18 years+ - NCT07589634RecruitingPhase 2
Tocilizumab to prevent side effects from ramantamig in multiple myeloma
This study tests whether a drug called tocilizumab can prevent serious side effects (cytokine release syndrome) when combined with a new cancer drug called ramantamig. You'll be eligible if you have multiple myeloma that has come back or stopped responding to prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT07377058Recruiting
Tocilizumab study for anti-MDA5 positive dermatomyositis
This trial tests if adding the drug tocilizumab to standard therapy helps people with a rare type of dermatomyositis (anti-MDA5 positive) that often affects the lungs. It compares tocilizumab to a placebo to see if it can improve symptoms and lung function.
Beijing, Beijing MunicipalityAges 18–65 - NCT07334379RecruitingPhase 2
Personalized treatment for hospitalized patients with breathing problems
This study tests a personalized approach for hospitalized patients with acute breathing problems. It uses a blood test to guide whether they receive a common steroid or a targeted medication (tocilizumab) to reduce inflammation, with the goal of improving recovery.
Toronto, OntarioAges 18 years+ - NCT05067348RecruitingPhase 2
Tocilizumab for generalized myasthenia gravis symptoms
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT06016179RecruitingPhase 1
Tocilizumab given through fluid-draining tubes for advanced cancer
This trial tests a drug called tocilizumab, which is given through the tube that drains fluid from your chest or belly. The goal is to see if it can help control cancer-related fluid buildup and improve symptoms.
Pittsburgh, PennsylvaniaAges 18–89 - NCT07006532Recruiting
Tocilizumab for chronic active antibody-mediated rejection
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
TehranAges 18 years+ - NCT06863480RecruitingPhase 1
Trial of tocilizumab for bleeding stroke to prevent later strokes
This trial tests if a drug called tocilizumab (TYENNE) can reduce the risk of delayed strokes after a bleeding stroke from a ruptured aneurysm. It is for adults who had a specific type of brain bleed and need a drain to remove fluid.
Gainesville, FloridaAges 18–89 - NCT06818266RecruitingPhase 3
Tocilizumab for severe chest crisis in sickle cell disease
This trial tests if the drug tocilizumab can help treat acute chest syndrome, a serious lung complication of sickle cell disease. It is for people with sickle cell disease who are hospitalized and need oxygen or breathing support. The study compares tocilizumab to a placebo to see if it speeds up recovery.
ParisAges 2 years+ - NCT06297096RecruitingPhase 3
Testing a two-drug combo for lung scarring in scleroderma
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Warsaw, Masovian VoivodeshipAges 18–74 - NCT05640271RecruitingPhase 2
Tocilizumab for acute chest syndrome in sickle cell
This trial studies tocilizumab (a medicine that calms inflammation) to treat acute chest syndrome in people with sickle cell disease. It may help improve symptoms and recovery by targeting key immune signals involved in this complication.
Chicago, IllinoisAges 12 years+ - NCT05609630RecruitingPhase 3
Testing two medicines for active systemic juvenile arthritis
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Phoenix, ArizonaAges 1–17 - NCT04691817RecruitingPhase 1/Phase 2
Testing tocilizumab plus atezolizumab after lung cancer treatment failure
This trial studies whether combining tocilizumab with atezolizumab can help people with advanced lung cancer that has already stopped responding to an immune checkpoint medicine. It may help when standard immune therapy (and other treatments) aren’t working anymore.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05833763RecruitingPhase 2
Glosfitamab plus pirtobrutinib for mantle cell lymphoma after BTK drugs
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
Parkville, VictoriaAges 18 years+ - NCT07825064RecruitingPhase 2
Cevostamab combination after CAR T-cell therapy for multiple myeloma
This trial tests a new drug, cevostamab, combined with two standard medicines (pomalidomide and dexamethasone) for people with multiple myeloma who have already had CAR T-cell therapy. It aims to see if this combination can help control the cancer better.
JenaAges 18 years+ - NCT02735707RecruitingPhase 3
Adaptive trial for severe pneumonia care in intensive care
This study tests ways to improve treatment for adults with severe pneumonia that lands them in the ICU, adjusting the plan as results come in. It may help your care team find better treatments for lung infection and breathing/heart support needs.
Jacksonville, FloridaAges 18 years+
What Tocilizumab is being studied for
Conditions with recruiting Tocilizumab studies.
Common questions
- Are there clinical trials studying Tocilizumab?
- Yes. Clin2 currently lists 54 recruiting studies that include Tocilizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tocilizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tocilizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tocilizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.